Publications by authors named "Drew Ribadeneyra"
Monoclonal antibodies targeting CD38 are important for treatment of both newly diagnosed and relapsed multiple myeloma (MM). Daratumumab and isatuximab are anti-CD38 antibodies with the US Food and Drugs Administration approval in multiple different combinations. Despite good initial efficacy, patients inevitably develop drug resistance.
View Article and Find Full Text PDFFunctional precision medicine offers a promising complement to genomics-based cancer therapy guidance by testing drug efficacy directly on a patient's tumor cells. Here, we describe a workflow that utilizes single-cell mass measurements with inline brightfield imaging and machine-learning based image classification to broaden the clinical utility of such functional testing for cancer. Using these image-curated mass measurements, we characterize mass response signals for 60 different drugs with various mechanisms of action across twelve different cell types, demonstrating an improved ability to detect response for several slow acting drugs as compared with standard cell viability assays.
View Article and Find Full Text PDFArticle Synopsis
- A phase 2 study evaluated a new treatment approach called Car-BiRd for multiple myeloma, combining carfilzomib and dexamethasone for induction, followed by lenalidomide and clarithromycin for consolidation, then lenalidomide maintenance.
- The treatment showed a high overall response rate of 94%, with 35% of patients achieving complete responses, although the results fell short of the study's goal of 55%.
- The regimen resulted in manageable low-grade toxicities and lower hematologic side effects compared to traditional combination therapies, demonstrating effectiveness particularly for patients who are not candidates for transplant.